On October 24, 2022, Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, announced the close of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. The total gross proceeds from the offering, before deducting underwriters’ discounts and commissions and estimated offering expenses, are approximately $316 million. All of the shares in the offering were offered by Denali Therapeutics.

The Wilson Sonsini team that advised Denali Therapeutics on the transaction included Tony Jeffries, Jennifer Knapp, Cathy Doxsee, Sara Dunton, and Rachel Slyker.

For more information, please see Denali Therapeutics' press release.